A clinical trial led by researchers at CU Anschutz has found that oral semaglutide, a medication widely used for diabetes and weight loss, reduces heavy drinking in adults with alcohol use disorder ...

The 24-week clinical trial will track more than 600 veterans nationwide to observe if the medication reduces alcohol cravings ...

A medication best known for treating diabetes and helping people lose weight is about to be studied for a very different use: ...

A clinical trial from the University of Colorado Anschutz found oral semaglutide, the medication behind Ozempic and Wegovy ...

The trial is taking place at 18 VA facilities, with the GLP-1 receptor semaglutide at the center of the research.

Researchers evaluated oral semaglutide in a randomized trial of 50 adults with Alcohol Use Disorder. The treatment reduced heavy drinking, alcohol cravings, and alcohol-related problems, supporting ...

The first published evidence from humans that semaglutide specifically reduces the symptoms of alcohol use disorder (AUD) has been published in The Journal of Clinical Psychiatry and details a recent ...

People with alcohol use disorder who took semaglutide, also known as Wegovy, drank less and had fewer cravings for alcohol, new research found. Reading time 3 minutes A study out this week suggests ...

A man prescribed semaglutide for obesity saw his drinking fall dramatically over 10 months, adding fresh real-world evidence to the idea that GLP-1 drugs may help curb alcohol cravings while ...

A study from the University of Colorado Anschutz found that the popular diabetes and weight loss drug reduced heavy drinking and alcohol-related harm in adults with Alcohol Use Disorder ...

AURORA, Colo., July 29, 2026 /PRNewswire/ -- A clinical trial led by researchers at CU Anschutz has found that oral semaglutide, a medication widely used for diabetes and weight loss, reduces heavy ...